Amgen Inc.

Sling Media Inc.

Credible Labs, Inc.

Brian Gregory Lucas

Timothy David Cushing

Xiaolin Hao

Felix Gonzalez Lopez De Turiso

Ilya Asnis

Yi Heng Chen

Lawrence R McGee

Robert Michael Rzasa

Dustin L McMinn

Padmanabha R Rao

Dawei Zhang

Youngsook Shin

Xiao He

Jason A Duquette

Andreas Reichelt

Minna Bui

Sean Curtis

Jacob A Kaizerman

Jennifer L Seganish

Frank Conway

Brian J Griffin

Jason Hirschhorn

Jay Patrick Powers

Robert J Zamboni

Richard J Austin

Stephen James Dash

George Matthew Raptis

Systems and methods are described for providing variable-length media clips based upon a received media stream. An exemplary system for providing media clips to users includes a database comprising a list of rules associated with a plurality of programs, as well as a first server and a second server. The first server receives information about a particular program being viewed by a media player and obtains rules from the database for the identified program that are transmitted to the media player. The second server receives a media clip of the particular program being viewed from the media player, wherein the media clip is created at the media player in accordance with the rules corresponding to the program, and subsequently makes the media clip available to the users.

Systems and methods for creating variable length clips from a media stream

The present invention involves a system and method for coordinating the centralization of the submission of requests for offers for credit and receipt of offers for credit between an internet user and a plurality of lending institutions via the internet. This method involves the use of a single offer request form, which is the combination of required lender information from consumer credit processes, and the receipt of information from the user, and various semi-automated online processes, to populate that single offer request form. After receiving this data, a special computer, or server, sorts the information and applies a filter to the data. The filter prepares that information for submission to lending institutions so that the lending institution may process the information and make a decision as to whether to offer the internet user credit. Once the data has been filtered, it is transmitted to a multiple number of lending institutions, or alternatively evaluated using a model of the lending institutions criteria. The method then allows for the lending institutions to submit responses on the information submitted back to the user and for those responses to be controlled and coordinated and displayed on an online account specific to the internet user via the internet.

Conditional transaction offer system and method

Systems and methods are described for establishing a connection between a client and a server that are each communicating via a network. The methods and techniques may be used, for example, to establish a media streaming connection between a media player and a placeshifting device when a firewall or other impediment to direct network connections exists. A relay server receives connection requests from the client and from the server via the network. In response to receiving the requests, a first connection is established between the relay server and the client and a second connection between the relay server and the server. Data received by the relay server on each of the first and second connections is relayed to the other of the first and second connections to thereby establish the connection between the client and the server via the relay server.

Systems and methods for establishing connections between devices communicating over a network

Substituted bicyclic heteroaryls having the following formula where the variables are as defined herein, and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110&#x25a1; activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110&#x3b4; activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

A method of determining whether live media content or time-shifted media content is received at a computing device such as a server or media player is presented. Attribute information concerning media content received at a communication device at a specific time is received and compared schedule information. The received media content is determined to be live media content if the media content identity agrees with the schedule information. The received media content is determined to be time-shifted media content if the media content identity does not agree with the schedule information.

Determination of receiving live versus time-shifted media content at a communication device

A method of determining whether live media content or time-shifted media content is received at a communication device is presented. In the method, attribute information concerning media content received at a communication device at a specific time is received. Also received is schedule information including an identity of media content carried at the specific time over a channel identified in the attribute information. The media content identity from the attribute information is compared with the media content identity from the schedule information. The received media content is determined to be live media content if the media content identity from the attribute information agrees with the media content identity from the schedule information. The received media content is determined to be time-shifted media content if the media content identity from the attribute information does not agree with the media content identity from the schedule information.

The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer. 

Pyridopyridazine compounds, compositions and methods of use

Substituted bicyclic heteroaryls having the structures: and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110&#x3b4; activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Growing community of inventors

San Francisco, CA, United States of America

Brian Gregory Lucas